Fact CheckerSign in

NCT00453674Recruiting

German Adrenocortical Carcinoma Registry

Deutsches Nebennieren-Karzinom-Register - German Adrenocortical Carcinoma Registry

Source: ClinicalTrials.gov · Last updated 24 Aug 2026

Brief summary (registry, in English)

Basic objective of the German Adrenocortical Carcinoma Registry is to improve the care of patients with adrenocortical cancer. The registration of as many patients as possible helps to collect data for the prognosis and prospects of success regarding different treatment plans. This data will be taken into consideration for planning prospective studies. With this registry, the recruitment of patients for prospective studies will be significantly facilitated. In this way - and in cooperation with networks in other countries (e.g. in Italy and France) - a structure allowing systematic improvement of therapy will be developed.

Status (registry)
Recruiting
Study type
Observational
Enrollment
1000 (estimated)
First submitted
28 Mar 2007
Start date
1 Jan 2003
Primary completion date
31 Dec 2030
Lead sponsor
University of Wuerzburg
NCT number
NCT00453674

What you commit to

  • Study type: Observational
  • Planned participants: 1000
  • From 1 Jan 2003 to the primary completion date, 31 Dec 2030
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

  • Histologically confirmed diagnosis of adrenocortical carcinoma

Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
University of Wuerzburg
Coordinator of this site? Confirm its status
WürzburgGermanyRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.